Any current/future new fundraising through debt or equity?

As of the latest update in the call (Q2 FY25), Vimta Labs does not have any current plans for fundraising through equity or preferential issues. Harita Vasireddi explicitly mentioned: "As of now, we don't have any thought in that direction" regarding fundraising. On the debt side, the company maintains a net debt-free balance sheet with total debt of INR116 million and a low debt-to-equity ratio (0.03x) as of September 30, 2024. Capex is ongoing with guidance of INR90 crores for FY25, mostly funded internally or through existing arrangements. Future fundraising needs have not been indi

Any current/future capex/capital investment/strategic investment?

Vimta Labs has placed an order for a second chamber for the electronics business, expected to be delivered in late Q4 or early Q1. Total infrastructure-related capex is around INR 70 crores, expected to be capitalized during Q3, with the majority already spent last year. Additional capex of INR 50-60 crores is planned, with nearly that amount already incurred in H1 FY25. Total capex guidance for FY25 remains around INR 90 crores. Expansion plans include adding one more EMI/EMC chamber for the electronics segment due to 80-85% current utilization, with a long lead time for installation.

Future growth expectations in sales/revenue/volumes?

Company targets INR 500 crores run rate revenue by FY26, aiming for INR125 crores quarterly run rate by Q3/Q4 of next year. Growth primarily driven by the pharmaceutical segment, including preclinical, clinical research, and analytical services. Food testing segment faced temporary setbacks due to lab relocations but expected to stabilize. Electronics testing business expanding with a new EMI/EMC chamber ordered, expected operational by late Q4 or early next year. Export revenue currently 25-30%, expected to remain steady; expansion has no direct link to export growth. Capacity expan

Future growth expectations in earnings/operating earnings/profits/EPS?

Vimta Labs aims to reach a revenue run rate of INR 500 crores in FY '26, up from about INR 85 crores quarterly currently. EBITDA margins are sustainable around current mid-30% levels, expected to maintain with capacity additions planned. Incremental revenue growth expected primarily from the pharmaceutical segment, which remains the dominant business. New life sciences facility and clinical trial services are key growth drivers contributing to improved revenues. Electronics business is expanding with an additional EMI/EMC chamber ordered to meet increasing demand. Preclinical and ana

Current/ Expected Orderbook/ Pending Orders?

An order has been placed for a second EMI/EMC chamber for the electronics business. Delivery of this chamber is expected in late Q4 or early Q1. Existing chamber capacities are currently utilized around 80% to 85%. No specific details on the overall current order book size or pending orders were disclosed. The management is proactively expanding capacity to accommodate anticipated growth without slowdown. There are ongoing contracts in the biosimilar and clinical trial segments, including preclinical and analytical services. Partnership discussions with major U.S. innovator companies are in ea

Vimta Labs LtdQ3 FY25

Vimta Labs Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹616P/E: 36.3Market Cap: ₹2.9K Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Company targets INR 500 crores run rate revenue by FY26, aiming for INR125 crores quarterly run rate by Q3/Q4 of next year.
→Growth primarily driven by the pharmaceutical segment, including preclinical, clinical research, and analytical services.
→Food testing segment faced temporary setbacks due to lab relocations but expected to stabilize.
→Electronics testing business expanding with a new EMI/EMC chamber ordered, expected operational by late Q4 or early next year.
→Export revenue currently 25-30%, expected to remain steady; expansion has no direct link to export growth.
→Capacity expansions and new facility commercialization from Q3 FY25 will support incremental volume growth (30-40% increase anticipated in some segments).
→Potential partnerships and new contracts arising from regulatory shifts (e.g., BIOSECURITY Act) may further boost volumes in the coming years.

Margin guidance

Category 3

→Vimta Labs aims to reach a revenue run rate of INR 500 crores in FY '26, up from about INR 85 crores quarterly currently.
→EBITDA margins are sustainable around current mid-30% levels, expected to maintain with capacity additions planned.
→Incremental revenue growth expected primarily from the pharmaceutical segment, which remains the dominant business.
→New life sciences facility and clinical trial services are key growth drivers contributing to improved revenues.
→Electronics business is expanding with an additional EMI/EMC chamber ordered to meet increasing demand.
→Preclinical and analytical segments within pharma are poised for growth, supported by complex generic studies and global client base.
→Capex of around INR 90 crores planned for FY '25 to support infrastructure and capacity expansion.
→Profit after tax and EPS have shown strong YoY growth, with PAT margins around 20% in Q2 FY '25.
→Company expects gradual revenue growth with operational leverage kicking in post capacity ramp-up.

3 more insights locked — sign up free to unlock

Fundraise plans

→As of the latest update in the call (Q2 FY25), Vimta Labs does not have any current plans for fundraising through equity or preferential issues.
→Harita Vasireddi explicitly mentioned: "As of now, we don't have any thought in that direction" regarding fundraising.
→On the debt side, the company maintains a net debt-free balance sheet with total debt of INR116 million and a low debt-to-equity ratio (0.03x) as of September 30, 2024.
→Capex is ongoing with guidance of INR90 crores for FY25, mostly funded internally or through existing arrangements.
→Future fundraising needs have not been indicated; the company appears comfortable with current financial resources and capex plans.

Order book

→An order has been placed for a second EMI/EMC chamber for the electronics business.
→Delivery of this chamber is expected in late Q4 or early Q1.
→Existing chamber capacities are currently utilized around 80% to 85%.
→No specific details on the overall current order book size or pending orders were disclosed.
→The management is proactively expanding capacity to accommodate anticipated growth without slowdown.
→There are ongoing contracts in the biosimilar and clinical trial segments, including preclinical and analytical services.
→Partnership discussions with major U.S. innovator companies are in early stages, mainly for cost-cutting related offshoring work.
→No definite updates on large order inflows related to the BIOSECURE Act yet, but some active discussions with major players are expected to mature by early next year.

Capex plans

Yes

→Vimta Labs has placed an order for a second chamber for the electronics business, expected to be delivered in late Q4 or early Q1.
→Total infrastructure-related capex is around INR 70 crores, expected to be capitalized during Q3, with the majority already spent last year.
→Additional capex of INR 50-60 crores is planned, with nearly that amount already incurred in H1 FY25.
→Total capex guidance for FY25 remains around INR 90 crores.
→Expansion plans include adding one more EMI/EMC chamber for the electronics segment due to 80-85% current utilization, with a long lead time for installation.
→No current plans for preferential equity or fundraising.
→The company is creating new facilities to house food testing and preclinical services, with significant ongoing investments.

How does Vimta Labs Ltd rank vs peers in ?

Pro feature

1Vimta Labs Ltd

Rev 3Mar 3

See full sector rankings

Want more stocks like Vimta Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio